Liver-Directed Therapy for Gastroenteropancreatic NETs in the Era of Peptide Receptor Radionuclide Therapy

Adrian Gonzalez-Aguirre; Etay Ziv

doi:10.1055/s-0040-1718388

Digestive Disease Interventions, Table of Contents

Digestive Disease Interventions 2020; 04(03): 282-290
DOI: 10.1055/s-0040-1718388

Review Article

Liver-Directed Therapy for Gastroenteropancreatic NETs in the Era of Peptide Receptor Radionuclide Therapy

Adrian Gonzalez-Aguirre

¹Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York

,

Etay Ziv

¹Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York

› Author Affiliations

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous group of tumors. Current treatment algorithms for these tumors are complex and often require a multidisciplinary approach. Recently, peptide receptor radionuclide therapy (PRRT) was granted Food and Drug Administration approval, making this treatment widely available in the United States. PRRT is now another therapeutic option for patients with GEP-NETs. To date there are no consensus guidelines about how to sequence multiple treatment options. Moreover, there is concern of potential liver toxicity when PRRT is used before or after liver-directed therapies (LDTs). In this review, we describe the characteristics of the most commonly used LDT and their potential interactions with PRRT, as well as specific clinical scenarios that are relevant when deciding on the use of LDT. We also review the limited case series that have been published involving patients treated with different combinations of LDT and PRRT. Finally, we discuss some of the future directions for GEP-NET treatments.

Keywords

embolization - liver-directed therapy - PRRT - hepatotoxicity

Full Text

References

References
1 Pavel M, Baudin E, Couvelard A. Barcelona Consensus Conference Participants. et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95 (02) 157-176
2 Dasari A, Shen C, Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3 (10) 1335-1342
3 Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007; 18 (03) 145-149
4 Panzuto F, Nasoni S, Falconi M. et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12 (04) 1083-1092
5 Hu P, Bai J, Liu M. et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer 2020; 23 (04) 591-599
6 Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res 2018; 10: 5629-5638
7 Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30 (05) 781-793
8 Rinke A, Wittenberg M, Schade-Brittinger C. PROMID Study Group. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology 2017; 104 (01) 26-32
9 Caplin ME, Pavel M, Ćwikła JB. CLARINET Investigators. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371 (03) 224-233
10 Strosberg J, El-Haddad G, Wolin E. NETTER-1 Trial Investigators. et al. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
11 Shah MH, Goldner WS, Halfdanarson TR. et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 2018; 16 (06) 693-702
12 Glazer ES, Tseng JF, Al-Refaie W. et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010; 12 (06) 427-433
13 Ejaz A, Reames BN, Maithel S. et al. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB (Oxford) 2018; 20 (03) 277-284
14 Chamberlain RS, Canes D, Brown KT. et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000; 190 (04) 432-445
15 Mohan H, Nicholson P, Winter DC. et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 2015; 26 (07) 935-942.e1
16 Groeschl RT, Pilgrim CH, Hanna EM. et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259 (06) 1195-1200
17 Brown KT, Nevins AB, Getrajdman GI. et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998; 9 (05) 822-828
18 Ho AS, Picus J, Darcy MD. et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188 (05) 1201-1207
19 Grozinsky-Glasberg S, Kaltsas G, Kaltsatou M. et al. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Endocrine 2018; 60 (03) 499-509
20 Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011; 28 (Suppl. 01) S286-S290
21 Chen JX, Rose S, White SB. et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol 2017; 40 (01) 69-80
22 Rindi G, Klimstra DS, Abedi-Ardekani B. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018; 31 (12) 1770-1786
23 Bosman FT, Hruban RH, Theise N. WHO Classification of Tumors of the Digestive System. 4th ed. Geneva: World Health Organization; 2010
24 Adesoye T, Daleo MA, Loeffler AG, Winslow ER, Weber SM, Cho CS. Discordance of histologic grade between primary and metastatic neuroendocrine carcinomas. Ann Surg Oncol 2015; 22 (Suppl. 03) S817-S821
25 Grillo F, Valle L, Ferone D. et al. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?. Endocrine 2017; 57 (03) 494-502
26 Grillo F, Albertelli M, Brisigotti MP. et al. Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology 2016; 103 (05) 452-459
27 Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials 2018; 19 (01) 390
28 Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) 2015; 17 (01) 29-37
29 Strosberg JR, Halfdanarson TR, Bellizzi AM. et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 2017; 46 (06) 707-714
30 Bushnell DL, Bodeker KL. Overview and current status of peptide receptor radionuclide therapy. Surg Oncol Clin N Am 2020; 29 (02) 317-326
31 Bodei L, Gilardi L, Volterrani D. et al. Neuroendocrine tumors: therapy with radiolabeled peptides. In: Strauss HW, Mariani G, Volterrani D, Larson SM. , eds. Nuclear Oncology: From Pathophysiology to Clinical Applications. Cham: Springer International Publishing; 2017: 1243-1267
32 Bhagat N, Reyes DK, Lin M. et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 2013; 36 (02) 449-459
33 Guiu B, Deschamps F, Aho S. et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 2012; 56 (03) 609-617
34 Soulen M, White S, Fidelman N. et al. Randomized embolization trial for neuroendocrine tumors (RETNET): first safety report. J Vasc Interv Radiol 2019; 30 (03) S49-S50
35 Padia SA, Lewandowski RJ, Johnson GE. et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol 2017; 28 (01) 1-15
36 Ezziddin S, Meyer C, Kahancova S. et al. ⁹⁰Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med 2012; 53 (11) 1663-1669
37 Hamiditabar M, Ali M, Bolek L, Vahdati G, Tworowska I, Delpassand ES. Safety and effectiveness of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy after regional hepatic embolization in patients with somatostatin-expressing neuroendocrine tumors. Clin Nucl Med 2017; 42 (11) 822-828
38 Elsayed M, Ermentrout RM, Sethi I. et al. Incidence of radioembolization-induced liver disease and liver toxicity following repeat ⁹⁰Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med 2020; 45 (02) 100-104
39 Braat MNGJA, van Erpecum KJ, Zonnenberg BA, van den Bosch MAJ, Lam MGEH. Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol 2017; 29 (02) 144-152
40 Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31 (05) 1237-1248
41 Lewandowski RJ, Memon K, Mulcahy MF. et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging 2014; 41 (10) 1861-1869
42 Kennedy AS, McNeillie P, Dezarn WA. et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin ⁹⁰Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74 (05) 1494-1500
43 Gil-Alzugaray B, Chopitea A, Iñarrairaegui M. et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57 (03) 1078-1087
44 Su YK, Mackey RV, Riaz A. et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol 2017; 28 (11) 1520-1526
45 Barraza J, Currie B, Nadolski G. et al. Delayed hepatotoxicity of Y-90 radioembolization. JVIR Scientific Session 2017; 28 (02) (S) S163-S164
46 Tomozawa Y, Jahangiri Y, Pathak P. et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol 2018; 29 (06) 858-865
47 Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019; 30 (12) 1915-1923
48 Maire F, Lombard-Bohas C, O'Toole D. et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology 2012; 96 (04) 294-300
49 Pericleous M, Caplin ME, Tsochatzis E, Yu D, Morgan-Rowe L, Toumpanakis C. Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes. Asia Pac J Clin Oncol 2016; 12 (01) 61-69
50 Fiore F, Del Prete M, Franco R. et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 2014; 47 (01) 177-182
51 Gupta S, Johnson MM, Murthy R. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
52 Strosberg J, Goldman J, Costa F, Pavel M. The role of chemotherapy in well-differentiated gastroenteropancreatic neuroendocrine tumors. Front Horm Res 2015; 44: 239-247
53 Woo S, Chung JW, Hur S. et al. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol 2013; 200 (06) 1370-1377
54 Devulapalli KK, Fidelman N, Soulen MC. et al. ⁹⁰Y radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology 2018; 288 (03) 774-781
55 Pavel M, O'Toole D, Costa F. Vienna Consensus Conference participants. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103 (02) 172-185
56 Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009; 96 (02) 175-184
57 Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015; 121 (08) 1172-1186
58 Hope TA, Bodei L, Chan JA. et al. NANETS/SNMMI consensus statement on patient selection and appropriate use of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy. J Nucl Med 2020; 61 (02) 222-227
59 Thang SP, Lung MS, Kong G. et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging 2018; 45 (02) 262-277
60 Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med 2019; 60 (03) 377-385
61 Tang LH, Untch BR, Reidy DL. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 2016; 22 (04) 1011-1017
62 Skoura E, Michopoulou S, Mohmaduvesh M. et al. The impact of ⁶⁸Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med 2016; 57 (01) 34-40
63 Nilica B, Waitz D, Stevanovic V. et al. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging 2016; 43 (09) 1585-1592
64 Riff BP, Yang YX, Soulen MC. et al. Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors. Clin Nucl Med 2015; 40 (11) 845-850
65 Braat AJAT, Ahmadzadehfar H, Kappadath SC. et al. Radioembolization with ⁹⁰Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol 2020; 43 (02) 246-253
66 Filippi L, Ciorra A, Sardella B, Schillaci O, Bagni O. Sequential use of (90)Y microspheres radioembolization and (177)Lu-Dotatate in pluri-metastatic neuroendocrine tumors: a case report. Nucl Med Mol Imaging 2014; 48 (04) 321-325
67 Braat AJAT, Kappadath SC, Ahmadzadehfar H. et al. Radioembolization with ⁹⁰Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol 2019; 42 (03) 413-425
68 Swärd C, Johanson V, Nieveen van Dijkum E. et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009; 96 (05) 517-521
69 Varker KA, Martin EW, Klemanski D, Palmer B, Shah MH, Bloomston M. Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE. J Gastrointest Surg 2007; 11 (12) 1680-1685
70 Pach D, Sowa-Staszczak A, Kunikowska J. et al. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope ⁹⁰Y-DOTA TATE, ¹⁷⁷Lu-DOTA TATE or ⁹⁰Y/¹⁷⁷Lu-DOTA TATE therapy in patients with disseminated NET. Radiother Oncol 2012; 102 (01) 45-50
71 Vaughan E, Machta J, Walker M, Toumpanakis C, Caplin M, Navalkissoor S. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Br J Radiol 2018; 91 (1091): 20180041
72 Severi S, Sansovini M, Ianniello A. et al. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging 2015; 42 (13) 1955-1963
73 Bodei L, Kidd MS, Singh A. et al. PRRT genomic signature in blood for prediction of ¹⁷⁷Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging 2018; 45 (07) 1155-1169
74 Bodei L, Kidd MS, Singh A. et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging 2020; 47 (04) 895-906
75 Jiao Y, Shi C, Edil BH. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331 (6021): 1199-1203
76 Marinoni I, Kurrer AS, Vassella E. et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 2014; 146 (02) 453-60.e5
77 Ziv E, Rice SL, Filtes J. et al. DAXX mutation status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression. J Vasc Interv Radiol 2018; 29 (11) 1519-1526
78 Kratochwil C, Giesel FL, López-Benítez R. et al. Intraindividual comparison of selective arterial versus venous ⁶⁸Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010; 16 (10) 2899-2905
79 Ebbers SC, Barentsz MW, Braat AJAT, Lam MGEH. Intra-arterial peptide receptor radionuclide therapy for neuroendocrine tumor liver metastases. Dig Dis Interv 2019; 3 (01) 81-90
80 Singh A, Zhang J, Kulkarni H, Baum R. Intra-arterial PRRT of SSTR-expressing tumors in patients with hepatic only versus extrahepatic tumor: efficacy and safety evaluation. J Nucl Med 2019; 60 (Suppl. 01) 625
81 Heath CL, Fidelman N, Bergsland E, Hope T. Intra-arterial peptide receptor radionuclide therapy using Y-90 DOTATOC for hepatic metastases of gastroenteropancreatic neuroendocrine tumors. NANETS 2019 Symposium Abstracts; 2019
82 Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020; 21 (01) 141
83 Strosberg JR, Weber JM, Choi J. et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 2012; 23 (09) 2335-2341
84 Soulen MC, van Houten D, Teitelbaum UR, Damjanov N, Cengel KA, Metz DC. Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. Pancreas 2018; 47 (08) 980-984
85 Anthony LB, Chauhan A, Wu J. et al. Antitumor efficacy of concurrent everolimus with hepatic transarterial bland embolization (evero-embo) in patients with metastatic well differentiated neuroendocrine tumor (NET). J Clin Oncol. 2019 ; abstract 4115
86 Yordanova A, Ahrens H, Feldmann G. et al. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors. Clin Nucl Med 2019; 44 (05) e329-e335
87 Lee D, Li M, Liu D. et al. Enhancing efficacy of PRRT for neuroendocrine tumors by combining with everolimus and histone deacetylase inhibitors. NANETS 2018 Symposium Abstracts; 2018
88 Maccauro M, Follacchio GA, Spreafico C, Coppa J, Seregni E. Safety and efficacy of combined peptide receptor radionuclide therapy and liver selective internal radiation therapy in a patient with metastatic neuroendocrine tumor. Clin Nucl Med 2019; 44 (04) e286-e288
89 Braat AJAT, Kwekkeboom DJ, Kam BLR. et al. Additional hepatic ¹⁶⁶Ho-radioembolization in patients with neuroendocrine tumours treated with ¹⁷⁷Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol 2018; 18 (01) 84